Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases
Funds will advance Ray Therapeutics’ optogenetics gene therapy programs for blinding retinal diseases.
Ray Therapeutics closes $6M seed financing to advance novel optogenetics platform to treat blinding diseases
Top-tier advanced therapies investor 4BIO Capital led the financing round.
The financing will be used to advance its lead optogenetics gene therapy Ray-001 into clinical trials for retinitis pigmentosa.